Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Equities researchers at HC Wainwright lowered their Q1 2025 earnings per share (EPS) estimates for Bradmer Pharmaceuticals in a research report issued on Friday, November 8th. HC Wainwright analyst M. Colonnese now expects that the company will post earnings per share of $0.47 for the quarter, down from their prior forecast of $0.52. HC Wainwright has a “Strong-Buy” rating on the stock. HC Wainwright also issued estimates for Bradmer Pharmaceuticals’ Q2 2025 earnings at $0.56 EPS, Q3 2025 earnings at $0.65 EPS, Q4 2025 earnings at $0.77 EPS and FY2025 earnings at $2.44 EPS.
Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported C($0.18) earnings per share for the quarter, topping the consensus estimate of C($0.52) by C$0.34.
Bradmer Pharmaceuticals Stock Performance
See Also
- Five stocks we like better than Bradmer Pharmaceuticals
- What is the Dogs of the Dow Strategy? Overview and Examples
- California Resources Stock Could Be a Huge Long-Term Winner
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Observability Wars: Datadog and Dynatrace Vie for Data Dominance
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
